MACK Merrimack Pharmaceuticals Inc.

4.08
+0.07  (+2%)
Previous Close 4.01
Open 4.02
Price To Book 0.81
Market Cap 54438559
Shares 13,342,784
Volume 49,892
Short Ratio
Av. Daily Volume 113,107

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181164871
  2. 8-K - Current report 181164703
  3. SC 13D - General statement of acquisition of beneficial ownership 181158045
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18996346
  5. 8-K - Current report 18996267

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial termination announced November 7, 2018.
MM-121 (SHERBOC)
HER2 negative metastatic breast cancer
Phase 2 data released June 25, 2018 - endpoints not met.
MM-141 - CARRIE
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
ONIVYDE
Cancer - second line pancreatic
Phase 2 trial discontinued due to futility - noted October 19, 2018.
MM-121 SHERLOC
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
ONIVYDE
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
ONIVYDE
Cancer - front line pancreatic
Phase 1 safety data due 1Q 2019.
MM-310
Solid tumors
Poster at ASCO June 2018.
MM-121
Solid tumors

Latest News

  1. John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman
  2. Edited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMT
  3. Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
  4. Research Report Identifies Merrimack Pharmaceuticals, PNM Resources, Inc. (Holding Co.), Carrols Restaurant Group, American Axle & Manufacturing, CBIZ, and Nova Measuring Instruments with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  5. Merrimack to shelve lead cancer drug, lay off most of workforce
  6. Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
  7. Merrimack Pharmaceuticals Q3 Earnings Preview
  8. 5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
  9. Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call
  10. Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
  11. Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials
  12. Merrimack Pharmaceuticals' stock plummets toward record low after cancer drug trial terminated
  13. Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
  14. Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack — What Drives Growth in Today's Competitive Landscape
  15. Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
  16. Merrimack Receives $5 Million Milestone Payment from Shire
  17. Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue?
  18. Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
  19. Edited Transcript of MACK earnings conference call or presentation 7-Aug-18 12:30pm GMT